Proof of efficacy of Kamillosan(R) cream in atopic eczema

Eur J Med Res. 2000 Apr 19;5(4):171-5.

Abstract

Kamillosan(R) cream contains chamomile extract as active principle manufactured from the chamomile sort Manzana which is rich in active principles and has been proved not to exhibit a chamomile-related allergen potential. For this reason Kamillosan(R) cream is suited for local therapy of atopic eczema. In a partially double-blind, randomized study carried out as a half-side comparison, Kamillosan(R) cream was tested vs. 0.5% hydrocortisone cream and the vehicle cream as placebo in patients suffering from medium-degree atopic eczema. After a 2-week treatment Kamillosan(R) cream showed a mild superiority towards 0.5% hydrocortisone and a marginal difference as compared to placebo.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Anti-Inflammatory Agents / administration & dosage
  • Arachidonic Acid / metabolism
  • Arm
  • Chamomile / therapeutic use
  • Dermatitis, Atopic / drug therapy*
  • Drug Combinations
  • Erythema / drug therapy
  • Humans
  • Hydrocortisone / administration & dosage
  • Middle Aged
  • Oils, Volatile / administration & dosage*
  • Phytotherapy
  • Plant Extracts / administration & dosage*
  • Plants, Medicinal
  • Pruritus / drug therapy
  • Sesquiterpenes / administration & dosage*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Drug Combinations
  • Oils, Volatile
  • Plant Extracts
  • Sesquiterpenes
  • Kamillosan
  • Arachidonic Acid
  • Hydrocortisone